A Systematic Review and Meta-Analysis Assessing the Accuracy of Blood Biomarkers for the Diagnosis of Ischemic Stroke in Adult and Elderly Populations.

Abstract

This study aims to elucidate the methodology and compare the accuracy of different blood biomarkers for diagnosing ischemic stroke (IS). We reviewed 29 articles retrieved from PubMed, MEDLINE, Web of Science, and CINAHL Plus with Full Text. Among these, 23 articles involving 3,494 participants were suitable for meta-analysis. The pooled area under the curve (AUC) of all studies for meta-analysis was 0.89. The pooled sensitivity and specificity were 0.76 (0.74-0.78) and 0.84 (0.83-0.86), respectively. Blood biomarkers from noninpatient settings demonstrated better diagnostic performance than those in inpatient settings (AUC 0.91 vs 0.88). Smaller sample sizes (<100) showed better performance than larger ones (≥100; AUC 0.92 vs 0.86). Blood biomarkers from acute IS (AIS) patients showed higher diagnostic values than those from IS and other stroke types (AUC 0.91 vs 0.87). The diagnostic performance of multiple blood biomarkers was superior to that of a single biomarker (AUC 0.91 vs 0.88). The diagnostic value of blood biomarkers from Caucasians was higher than that from Asians and Africans (AUC 0.90 vs 0.89, 0.75). Blood biomarkers from those with comorbidities (AUC 0.92) showed a better diagnostic performance than those not reporting comorbidities (AUC 0.84). All the subgroups analyzed, including setting, sample size, target IS population, blood biomarker profiling, ethnicity, and comorbidities could lead to heterogeneity. Blood biomarkers have demonstrated sufficient diagnostic accuracy for diagnosing IS and hold promise for integration into routine clinical practice. However, further research is recommended to refine the optimal model for utilizing blood biomarkers in IS diagnosis.